Misoprostol as a Treatment for Endometrial Polyps in Infertile Patients

Last updated: February 13, 2020
Sponsor: Henry Aristoteles Mate-Sánez
Overall Status: Completed

Phase

2/3

Condition

Leiomyomas

Uterine Fibroids

Polyps

Treatment

N/A

Clinical Study ID

NCT04270994
MSP_2016
  • Ages 18-45
  • Female

Study Summary

Endometrial polyps are one of the main causes of infertility in women. In this work we propose an alternative, effective, economical and safe treatment: the use of misoprostol

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Women with uterine polyps diagnosed by endovaginal ultrasound and/orhysterosonography, female ≤ 45 years of age

Exclusion

Exclusion Criteria:

  • Patients older than 45 years, polyps larger than 60 mm, who did not performsurveillance and/or minimum assessment 6 months after medical management

Study Design

Total Participants: 54
Study Start date:
September 01, 2016
Estimated Completion Date:
November 30, 2019

Study Description

The prevalence of uterine polyps has been estimated in the general population at 10-15%, while in infertile patients it ranges from 6-32%. Its etiology is considered as multifactorial. Polyps induce a local inflammatory response in the endometrial cavity, causing infertility. The treatment of choice considered "gold standard" is the excision by hysteroscopy, however, improvement has been shown in patients with conservative management due to the regression rate of 27%. There are no recommended drugs to provide a definitive treatment for uterine polyps. Misoprostol is a synthetic analogue derived from prostaglandin E1 that has stimulating effects on the smooth muscle fibers of the uterus, causing contractions of the myometrium, which cause endouterine evacuation. The present study shows a possible utility of misoprostol for the conservative treatment of uterine polyps.